MINNEAPOLIS (Jan. 10, 2017) – Pharmacogenomics company OneOme today announced the U.S. Patent and Trademark office has issued “Patent Pending” status for its RightMed pharmacogenomic test and RightMed Advisor, an online tool for providers to quickly and easily interpret test results and gain access to an expert pharmacogenomic knowledge base.
The patent pending status applies to four areas outlined in OneOme’s single, non-provisional patent application, including:
• Knowledge curation – OneOme’s method and process for acquiring and integrating data to create the organization’s knowledge base;
• Haplotyper engine – The computational method, algorithms and software for transforming genomic variations into haplotypes/genotypes and for dealing with complex combinations of gene mutations to determine probable genotypes/phenotypes and the most likely haplotype;
• Reporting algorithm – The complex computational methods and algorithms which help OneOme determine and assign a drug impact score to every drug within the OneOme product; and
• RightMed Advisor – The interactive reporting system and decision support tool used by physicians to gain insight into the pharmacologic impact of genomic variants, drug-drug interactions, a summary of pharmacogenomic clinical guidelines, and curated lists of alternative medications.
“Obtaining the patent-pending status for the OneOme platform is significant,” said Paul Owen, CEO of OneOme. “It provides proof of our proprietary knowledge and underscores the unique solution OneOme provides, via a sophisticated and complex algorithm, to determine appropriate prescription drugs based on individual patients’ DNA.”
OneOme’s RightMed test was developed to offer a cost-effective, comprehensive, personalized pharmacogenomic analysis of 22 genes provided as part of routine clinical care. The test helps providers easily make personalized treatment decisions across more than 340 medications. OneOme has also developed a platform for clients to generate the interpretative drug report using genotype or sequence data obtained elsewhere, all with the goal of better identifying which prescription medications may work best for individual patients.
“This patent signifies not only our commitment to bringing evidence-based pharmacogenomics testing to the market, but also to providing technology that goes beyond typical lab solutions to enable patients and providers to make their results actionable in everyday care,” said Jason Ross, OneOme’s Chief Technology Officer.
The OneOme platform brings pharmacogenomics into routine clinical care. By using a physician-ordered cheek swab test taken at home or as part of a doctor’s visit, physicians will have a better idea of how their patients’ 22 genes analyzed through the test will respond to various medications.
Anyone can take the RightMed test, although some patients who may benefit most include: those who are taking some classes of medication, such as cardiovascular or psychiatric patients; those who are struggling with adverse drug reactions, medications that are not working; or those who are on multiple medications.
“Ultimately, our goal is to help physicians and their patients as they select the most effective prescription for their unique DNA in the most timely manner possible,” Owen continued. More than half of the four billion prescriptions issued each year in the U.S. do not work as intended and adverse drug reactions are now the fourth-leading cause of death.
OneOme also recently began integrating the test results into what is commonly called an EMR, or electronic medical record. This will make it easier for physicians to order the RightMed test and see its results electronically throughout the patient’s lifetime.
While the RightMed test is available globally, OneOme has formal partnerships with High Profile Laboratory in Guaynabo, Puerto Rico, to serve Puerto Rico, Cuba and the Dominican Republic. The company also operates in partnership with Medcan, Canada’s largest executive health clinic, and recently announced the additions of Minnesota-based Ridgeview Medical Center and Centra Health’s Stroobants Cardiovascular Center in Central Virginia to its provider network.
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit www.oneome.com.